MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA – Get Free Report) passed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $1.18 and traded as high as $1.25. MAIA Biotechnology shares last traded at $1.25, with a volume of 1,822,036 shares.
Trending Headlines about MAIA Biotechnology
Investors following MAIA have been watching these headlines:
- Positive Sentiment: MAIA reported an 88% disease control rate in the expanded Phase 2 THIO-101 study, evaluating ateganosine as a third-line treatment for advanced NSCLC. The company said the results are consistent with strong efficacy observed in earlier study parts; further Part C data could support an accelerated-approval filing. MAIA reports THIO-101 efficacy data
- Positive Sentiment: Diamond Equity raised its projected earnings per share for FY2026 and FY2027, forecasting smaller losses than previously expected. This is a modestly favorable analyst revision, though MAIA is still expected to remain loss-making. MAIA analyst estimates
- Neutral Sentiment: The reported efficacy is interim Phase 2 evidence, and the company is gathering additional data. The anticipated 2027 survival analysis remains an important future readout; the current update does not establish definitive survival benefit or approval. Interim Phase 2 efficacy data
MAIA Biotechnology Stock Up 23.8%
The firm has a fifty day moving average price of $1.18 and a two-hundred day moving average price of $1.39. The stock has a market capitalization of $77.19 million, a P/E ratio of -2.66 and a beta of 0.28.
Insider Activity
In other news, Director Ramiro Guerrero acquired 37,595 shares of MAIA Biotechnology stock in a transaction on Thursday, September 10th. The stock was acquired at an average cost of $1.32 per share, for a total transaction of $49,625.40. Following the purchase, the director owned 773,296 shares in the company, valued at $1,020,750.72. This trade represents a 5.11% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Vlad Vitoc bought 73,000 shares of the firm’s stock in a transaction on Monday, September 14th. The stock was purchased at an average cost of $1.37 per share, with a total value of $100,010.00. Following the completion of the acquisition, the chief executive officer directly owned 1,049,121 shares of the company’s stock, valued at approximately $1,437,295.77. The trade was a 7.48% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 258,078 shares of company stock worth $352,426 over the last three months. 19.81% of the stock is currently owned by insiders.
Institutional Investors Weigh In On MAIA Biotechnology
Institutional investors have recently made changes to their positions in the company. PVG Asset Management Corp purchased a new stake in shares of MAIA Biotechnology during the first quarter valued at approximately $46,000. Susquehanna International Group LLP purchased a new position in MAIA Biotechnology in the 2nd quarter worth approximately $51,000. StoneX Group Inc. purchased a new position in MAIA Biotechnology in the 3rd quarter worth approximately $78,000. Empowered Funds LLC purchased a new position in MAIA Biotechnology in the 3rd quarter worth approximately $88,000. Finally, Marshall Wace LLP purchased a new position in MAIA Biotechnology in the 3rd quarter worth approximately $100,000. Hedge funds and other institutional investors own 5.65% of the company’s stock.
MAIA Biotechnology Company Profile
MAIA Biotechnology is a clinical-stage biopharmaceutical company focused on developing cancer treatments. Its research centers on therapies that target telomeres, protective structures at the ends of chromosomes that can help cancer cells continue to divide. The company’s lead drug candidate, ateganosine (also known as THIO or 6-thio-dG), is designed to disrupt telomeres in cancer cells and promote their death. MAIA has evaluated ateganosine in clinical research, including studies involving patients with advanced non-small cell lung cancer and treatment in combination with the immunotherapy cemiplimab.
See Also
- Five stocks we like better than MAIA Biotechnology
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for MAIA Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAIA Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
